Abstract
Administering erythropoietin to rats with diabetic neuropathy prevents and partly reverses biochemical and physical deficits in nerve and muscle. Certain drawbacks limit the immediate applicability of this approach in patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
